New agent developed for prostate cancer diagnosis, treatment

An agent called PSMA-617 is capable of attaching specifically to prostate cancer cells. This agent can be labeled with various radioactive substances. When chemically bound to a weakly radioactive diagnostic radionuclide, it can detect prostate tumors and their metastases in PET scans. If labeled with a strongly radioactive therapeutic radionuclide, PSMA-617 can specifically destroy cancer cells. A first clinical application of this radiopharmaceutica has now delivered promising results. (Mehr in: Cancer News — ScienceDaily)